LSTA (Lisata Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

LSTA (Lisata Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

LSTALisata Therapeutics, Inc.

Mkt Cap$44M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1M

Net Income (TTM)-$18M

EPS (TTM)-$2.13

Free Cash Flow (TTM)-$17M

Gross Margin100.0%

Op. Margin-1876.4%

Net Margin-1704.9%

FCF Margin-1615.3%

P/S Ratio (TTM)41.5x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$7M
Q2 23	$0	$0	-$7M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$6M
Q1 24	$0	$0	-$7M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$5M
Q4 24	$1M	$1M	-$5M
Q1 25	$0	$0	-$6M
Q2 25	$70K	$70K	-$5M
Q3 25	$0	$0	-$4M

Valuation

Quarter	P/S	P/E
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	44.4x	—
Q1 25	44.4x	—
Q2 25	41.5x	—
Q3 25	41.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$6M	-$6M
Q1 23	-$8M	-$8M
Q2 23	-$4M	-$4M
Q3 23	-$4M	-$4M
Q4 23	-$4M	-$4M
Q1 24	-$7M	-$7M
Q2 24	-$5M	-$5M
Q3 24	-$3M	-$3M
Q4 24	-$5M	-$5M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$3M	-$3M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$26K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$28K
Q2 25	$28K
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	-4.5%
Q1 23	—	+3.4%
Q2 23	—	+2.3%
Q3 23	—	-84.2%
Q4 23	—	-7.9%
Q1 24	—	-3.6%
Q2 24	—	-19.7%
Q3 24	—	-10.5%
Q4 24	—	-1.3%
Q1 25	—	-11.4%
Q2 25	—	-10.6%
Q3 25	—	-17.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$468K	—
Q1 23	$675K	—
Q2 23	$0	—
Q3 23	$307K	—
Q4 23	$473K	—
Q1 24	$454K	—
Q2 24	$237	—
Q3 24	$327K	—
Q4 24	$872K	87.2%
Q1 25	$530K	—
Q2 25	$239K	341.4%
Q3 25	$232K	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$3M	$3M
Q1 23	$3M	$4M
Q2 23	$3M	$4M
Q3 23	$3M	$3M
Q4 23	$3M	$3M
Q1 24	$3M	$3M
Q2 24	$3M	$3M
Q3 24	$3M	$3M
Q4 24	$3M	$3M
Q1 25	$3M	$3M
Q2 25	$2M	$3M
Q3 25	$2M	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$32M	$37M	$69M
Q1 23	$28M	$33M	$61M
Q2 23	$24M	$34M	$58M
Q3 23	$32M	$22M	$54M
Q4 23	$23M	$28M	$51M
Q1 24	$22M	$22M	$43M
Q2 24	$28M	$10M	$38M
Q3 24	$20M	$16M	$36M
Q4 24	$16M	$15M	$31M
Q1 25	$20M	$6M	$26M
Q2 25	$17M	$5M	$22M
Q3 25	$19M	$0	$19M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	5M	+4.6%
Q1 23	8M	+60.9%
Q2 23	8M	+0.4%
Q3 23	8M	+1.5%
Q4 23	8M	-0.0%
Q1 24	8M	+1.9%
Q2 24	8M	+0.2%
Q3 24	8M	+0.2%
Q4 24	8M	+0.1%
Q1 25	9M	+3.3%
Q2 25	9M	+0.0%
Q3 25	9M	+1.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	$136K	108
FY 14	$99K	182
FY 15	$102K	221
FY 16	$169K	209
FY 17	$0	22
FY 18	$0	25
FY 19	$0	27
FY 20	$0	24
FY 21	$0	27
FY 22	$0	27
FY 23	$0	25
FY 24	$38K	26